ImmunoGen, Inc. (NASDAQ:IMGN) Q3 2023 Earnings Call Transcript

And you can imagine or hypothesize that if the clinician is even considering a monotherapy non-platinum agent in the clinical trial like mirvetuximab that when we see the final data, I would expect that we’d have a substantial proportion of patients that have a short — relatively short platinum-free interval. And that’s really important to help interpret the full data set, along with the proportion of patients that have prior exposure to PARP inhibitors and bevacizumab. So it’s all of those clinical factors and demographics that needs to be incorporated into the interpretation of the data to be able to put the data into context with respect to the objective response rate and durability of response. And with respect to your question around NCCN, I think a working assumption should be that the NCCN is looking for published data sets to review in the context of updating their guidelines.

Mark Enyedy: We have time for one more question.

Operator: Certainly. Our last question are coming from the line of Lee Chen with HC

Unidentified Analyst: Can you hear me okay?

Mark Enyedy: Yes.

Unidentified Analyst: Yes. So just upon the conversion from accelerated approval ELAHERE to full approval, I believe that Takeda — under the license agreement with Takeda, there’s additional payment. Can you provide more details on that?

Mark Enyedy: So I can comment on the Huadong license, and that does call for additional milestone payments upon full approval. I won’t comment on the exact amount of those. I would have to get back to you on the Takeda license. Okay. Well, thank you all for joining us today. Obviously, we are very pleased with the progress in the business. We’ve got an important and growing product. We look forward to continued progress there. So we look to expand geographically and also moving this drug into earlier lines of therapy. We’ve got an important second pivotal program ongoing as we speak, an exciting portfolio. And you’ll hear more from us as we go forward about reinvesting in the pipeline and our research capabilities. We think that ADCs are an important and growing class of therapeutics. We’ve got a highly differentiated skill set as it relates to that class of therapy. So again, I look forward to keeping you updated, and we’ll see many of you at ASH. Thanks.

Operator: Ladies and gentlemen, that does end our conference for today. Thank you for your participation. You may now disconnect.